McGill University Health Center, Montreal, Québec, Canada.
McGill University Health Center, Montreal, Québec, Canada.
Semin Fetal Neonatal Med. 2017 Oct;22(5):328-335. doi: 10.1016/j.siny.2017.07.009. Epub 2017 Jul 22.
Albumin is one of the most abundant proteins in plasma and serves many vital functions. Neonatal concentrations vary greatly with gestational and postnatal age. In critically ill neonates, hypoalbuminemia occurs due to decreased synthesis, increased losses or redistribution of albumin into the extravascular space, and has been associated with increased morbidities and mortality. For that reason, infusion of exogenous albumin as a volume expander has been proposed for various clinical settings including hypotension, delivery room resuscitation, sepsis and postoperative fluid management. Albumin is often prescribed in infants with hypoalbuminemia, hyperbilirubinemia, and protein-losing conditions. However, the evidence of these practices has not been reviewed or validated. Albumin infusion may initiate highly complex processes that vary according to the individual and disease pathophysiology. Indeed, it may be associated with harms when misused. In this review, we critically appraise the scientific evidence for administering albumin in most conditions encountered in the neonatal intensive care unit, while emphasizing the benefits and risks associated with their use.
白蛋白是血浆中最丰富的蛋白质之一,具有许多重要功能。新生儿的白蛋白浓度随胎龄和出生后年龄变化很大。在危重新生儿中,由于白蛋白合成减少、丢失增加或重新分布到血管外空间,会出现低白蛋白血症,并与发病率和死亡率增加相关。因此,在外周循环低血压、产房复苏、败血症和术后液体管理等各种临床情况下,已提出输注外源性白蛋白作为容量扩张剂。白蛋白常被开给患有低白蛋白血症、高胆红素血症和蛋白丢失性疾病的婴儿。然而,这些做法的证据尚未经过审查或验证。白蛋白输注可能会引发高度复杂的过程,这些过程因个体和疾病病理生理学而异。事实上,当被滥用时,它可能会带来危害。在这篇综述中,我们批判性地评估了在新生儿重症监护病房中遇到的大多数情况下使用白蛋白的科学证据,同时强调了与使用相关的益处和风险。